could slow the progression of motor symptoms in people with advanced forms of the condition. Although this shows promise to be a disease-modifying treatment for Parkinson’s, it is unclear whether the drug actually clears the proteins from the brain.
While some existing treatments aim to ease these symptoms by improving dopamine levels in the brain, their long-term effects are limited. So far, there are no approved disease-modifying therapies that halt or slow the progression of Parkinson’s.at Swiss pharmaceutical company Roche and his colleagues recruited 316 people who were thought to have early-stage Parkinson’s disease.
These individuals had rapid eye movement sleep behaviour disorder, where people act out intense and often violent dreams, which is common in Parkinson’s; were takingcalled MAO-B inhibitors to manage their symptoms; or had been rated by their specialist as being at stage two out of five on a symptom scale, with a higher number indicating greater severity.
For example, based on a Parkinson’s disease rating scale for motor symptoms, those on MAO-B inhibitors who then received placebo infusions scored 6.82 at the end of the year, while those taking both the inhibitors and prasinezumab scored 4.15.
Car Car Latest News, Car Car Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: newscientist - 🏆 541. / 51 Read more »